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Background: Prostate cancer is a leading cause of death in the male population of the western world. Human
kallikrein-related peptidase 2 (hK2) is abundantly expressed in malignant prostatic tissue, and its gene, KLK2, is regulated
by the androgen receptor. 11B6 is a murine IgG1 monoclonal antibody directed against free human hK2. In this study,
we performed a preclinical evaluation of 111In-labelled 11B6 in mouse xenografts to investigate its potential in the
clinical staging and assessment of metastatic prostate cancer.
Methods: 11B6 was radiolabelled with 111In through CHX-A″-DTPA chelation. In vivo biodistribution and uptake of
111In-DTPA-11B6 were measured until 168 h post-injection in NMRI nude mice bearing subcutaneous LNCaP xenografts.
The binding specificity to hK2 was evaluated by both in vivo competitive binding assays with excess non-labelled 11B6
and hK2-negative DU145 xenografts. SPECT/CT imaging of subcutaneous and intra-tibial LNCaP xenografts was used to
visualize the tumours.
Results: Tumour uptake of 111In-DTPA-11B6 in LNCaP xenografts was 19% ± 0.78%IA/g at 48 h, giving a tumour-to-
blood ratio of 1.6, which increases to 2.4 at 1 week post-injection. Accumulation was low in other organs except for
the salivary glands, which is probably the result of cross-reactivity with mouse kallikreins. Significantly lower tumour
accumulation was observed in competitive assays and DU145 xenografts. SPECT/CT imaging could clearly visualize the
subcutaneous and intra-tibial LNCaP xenografts.
Conclusions: Our study demonstrates the potential of 111In-DTPA-11B6 for the detection of metastatic prostate cancer
and monitoring anti-androgen therapy, as it exhibits an increased uptake and accumulation in viable tumour when
compared to normal tissue. A humanised version of the 11B6 monoclonal antibody is currently under evaluation.
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Molecular imagingBackground
Although improvements have been made in approaches
for both diagnosis and treatment, prostate cancer (PCa)
remains the second leading cause of cancer-related deaths
in the male population of the western world [1]. The ratio
of local-regional PCa to that of metastatic disease has in-
creased since the introduction of prostate-specific antigen
(PSA) testing, subsequently raising questions regarding* Correspondence: oskar.vilhelmsson_timmermand@med.lu.se
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distribution, and reproduction in any medium,overdiagnosis [2,3]. Nevertheless, there is a need for new
molecular imaging moieties to improve the clinical staging
and monitoring of PCa in order to identify the optimal
course of treatment for the disease.
Today, molecular imaging methods based on meta-
bolic markers such as 18F-FDG (fluorodeoxyglucose) and
18F/11C-Choline are commonly used; however, there are
known limitations for these tracers. 18F-FDG works well
in a more advanced disseminated disease, but is ineffect-
ive in detecting localized PCa because of its lower glyco-
lytic uptake compared to other neoplasms [4]. Also, the
normal elimination of 18F-FDG through the urinary bladdere Springer. This is an Open Access article distributed under the terms of the
reativecommons.org/licenses/by/4.0), which permits unrestricted use,
provided the original work is properly credited.
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nodes [5]. 18F/11C-Choline is the most common radiotracer
in PCa imaging today, and while they perform better than
18F-FDG, they are still limited in their ability to differentiate
between a localized PCa and benign disease [6].
Molecular imaging of androgen receptor (AR) signalling
holds the promise for more accurate disease evaluation
and therapeutic monitoring, with additional implications
for hormonal treatment and radiation therapy in PCa.
PCa growth is dependent on androgens that signal
through the AR and plays a fundamental role in cancer
cell proliferation, apoptosis and invasion/metastasis [7].
A newly developed radiotracer, 18F-FDHT (16β-[18F]
fluoro-5α-dihydrotestosterone), enables the imaging of
AR expression. Furthermore, preliminary clinical stud-
ies demonstrated that 18F-FDHT might provide for the
imaging of AR expression during disease progression in
castration-resistant PCa [8].
The commercially available ProstaScint®, 111In-capro-
mab pendetide, targets an intracellular epitope of the
prostate-specific membrane antigen (PSMA) [9], another
surrogate of AR signalling. Promising results were recently
reported using a new antibody (J591) against an extracel-
lular domain of the PSMA molecule and presents as a
possibility to suppress PSMA expression following anti-
androgen treatments [10]. However, the PSMA expression
in other tissues such as the human brain [11] hampers this
approach to PCa imaging.
An alternative strategy could be to target AR-dependent
antigens such as PSA and hK2 as they express almost
exclusively in the prostate tissue [12,13]. Both PSA and
hK2 are serine proteases, encoded by the human kallikrein
genes KLK3 and KLK2 located on chromosome 19, re-
spectively, and are well characterized as AR-regulated
genes [14-16]. These kallikreins are produced by the same
secretory luminal cells in the prostate and share an 80%
amino acid homology, as well as several structural simi-
larities [15-17]. Importantly, the PSA and hK2 antigens
are abundantly expressed in malignant prostate tissue
throughout all clinical stages. Recent publications on
the 5A10 [18] and PSA30 antibodies [19] have explored
the concept of PSA imaging, including targeting the
free, unbound forms of prostate-specific antigen (fPSA).
Results from animal studies using the PSA30 antibody
showed a selective uptake in LNCaP tumours in vivo;
however, the retention was faint and most likely due to
shortcomings in the 125I-labelling method. In addition,
89Zr-labelled 5A10 exhibited better imaging capabilities but
was accompanied by increased liver uptake. Nonetheless,
this PET tracer was sufficient in detecting AR-dependent
changes in PSA expression levels in mouse tumour lesions,
as well as in distinguishing PCa cells within bone lesions -
both of which may be useful in the staging and clinical
evaluation of advanced prostate cancer [18].Regardless of the similarities between PSA and hK2,
hK2 displays properties distinct from those of PSA. hK2
has been used in immunoassays to improve the accuracy
of PCa screening [17,20]. In serum, most hK2 is in its
free form, although the total levels of hK2 are in the
range of 1% total PSA but similar to that of fPSA [21].
As a tissue marker for PCa, the hK2-specific immuno-
staining pattern differs from that of PSA, with an in-
creased intensity in the PCa tumour and lymph node
metastases compared to that observed in benign tissue
[22,23]. Moreover, the very-low-to-no expression in
other organs [12,13] makes hK2 a potential target candi-
date for PCa imaging.
Owing to these potentially advantageous characteristics
of hK2 as a PCa biomarker, we investigated the possibility
of targeting free hK2 in an androgen-dependent PCa
model using 111In-radiolabelled 11B6 - a murine IgG1
hK2-specific monoclonal antibody previously used in im-
munoassays for free hK2 [24]. Here, we discuss the results
of in vivo hK2 imaging with 111In-labelled 11B6 in AR-
positive LNCaP xenografts.
Methods
Antibody conjugation and radiolabelling
The murine monoclonal antibody, 11B6, was first described
and characterized by Vaisanen et al. [24] and was provided
by the University of Turku (Turku, Finland) for this study.
Conjugation and radiolabelling was performed as previously
described by Tolmachev et al. [25]. Briefly, 2 mg of 11B6
was conjugated with the chelator CHX-A″-DTPA (B-355,
Macrocyclics; Dallas, TX, USA) through the isothiocyanate
functional group. A solution of 11B6 (4 to 5 mg/mL in
PBS) was adjusted to pH 9.2 using 0.07 M sodium bor-
ate buffer (Sigma Aldrich; St. Louis, MO, USA). CHX-
A″-DTPA was then added to the protein solution at a
molar ratio of 3:1 (chelator to antibody) and incubated
at 40°C with gentle shaking. The reaction was termi-
nated after 4 h, and CHX-A″-DTPA-11B6, henceforth
referred to as DTPA-11B6, was separated from the free
chelate by size-exclusion chromatography on a NAP-5 col-
umn (GE Healthcare; Uppsala, Sweden) equilibrated with
20 mL of 0.2 M ammonium acetate buffer (Sigma Aldrich),
pH 5.5. Conjugated 11B6 was eluted with 1 mL of am-
monium acetate buffer, and aliquoted samples were
stored at −20°C.
For radiolabelling, approximately 125 μL of DTPA-11B6
(approximately 1 μg/μL in 0.2 M ammonium acetate buffer
pH 5.5) was mixed with a predetermined amount (approxi-
mately 50 to 100 MBq) of 111InCl3 (Mallinckrodt Medical;
Dublin, Ireland), incubated at room temperature for 1.5 to
2 h and then purified on a NAP-5 column (GE Healthcare)
equilibrated with PBS (Thermo Scientific; Waltham, MA,
USA). Labelling efficiency and kinetics were monitored by
instant thin-layer chromatography (ITLC) (Biodex, Shirley,
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In this system, the radiolabelled conjugate remains at
the origin line, while free 111In and 111In-DTPA migrate
with the solvent front. The radioactive distribution was
determined using a Cyclone Storage Phosphor System
with Optiquant quantification software (Perkin Elmer;
Waltham, MA, USA).Binding kinetics with surface plasmon resonance
The 11B6 binding kinetics were analysed by surface
plasmon resonance using a Biacore 2000 (Biacore AB;
Uppsala, Sweden). The affinity of 11B6 to hK2 before
and after CHX-A″-DTPA conjugation was determined.
The hK2 antigen, provided by the University of Turku
(Department of Biotechnology; Turku, Finland), was
produced and purified as previously described [26].
hK2 antigen (25.9 μg/mL in 10 mM sodium acetate
buffer pH 4.0 (Sigma Aldrich)) was immobilized on a
CM4 research grade chip (Biacore AB) by amino coupling
using N-hydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethy-
laminopropyl) carbodiimide hydrochloride (EDC) and 1 M
ethanolamine hydrochloride-NaOH, pH 8.5, in a Biacore
2000 system. Samples were flown over two flow cells, one
being a blank reference, in five different concentrations
ranging from 0.5 to 100 nM to detect eventual binding.
One of the two flow cells contained immobilized hK2,
while the other was served as a blank reference. The bind-
ing kinetics were studied in a 3-min-long association phase
and a 15-min-long dissociation phase with a flow rate
of 30 μL/min, followed by regeneration with 25 mM
glycine buffer pH 2.7. Kinetic constants were calculated
using a 1:1 Langmuir binding model with correction for
mass transfer. BIAEvaluation 4.1 software (Biacore AB)
was used for calculations.Stability studies
The stability of 111In-DTPA-11B6 was assessed in tripli-
cate by incubating the compound at 4°C in PBS buffer
or at 37°C in murine serum collected from normal
NMRI mice. For stability in PBS, 1 μL (n = 3) was taken
at 1, 2, 3 and 7 days and analysed by ITLC. For stability
in serum, 10 μL of 111In-DTPA-11B6 (corresponding to
3 μg of antibody with 0.8 to 0.9 MBq 111In) was mixed
with 100 μL of mouse serum. Approximately 20 μL of
each mixture was collected after 2, 3 and 9 days of incu-
bation and analysed by SDS-PAGE on a NuPAGE 4% to
12% Bis-Tris gel (Invitrogen; Carlsbad, CA, USA) in
MES buffer (200 V constant, approximately 30 min).
111In-DTPA and free 111In diluted in PBS were run in par-
allel with the incubated sample as controls. The distribu-
tion of the samples along the gel was evaluated using a
Cyclone Storage Phosphor System (Perkin Elmer).Cell lines
LNCaP and DU145 were purchased from American
Type Culture Collection (ATCC; Manassas, VA, USA)
and cultured in RPMI 1640 medium (Thermo Scientific)
supplemented with 10% foetal bovine serum (Thermo
Scientific) with 100 U/mL penicillin and 100 μg/mL
streptomycin (Thermo Scientific). The cells were main-
tained at 37°C in a humidified incubator at 5% CO2 and
were detached with trypsin-EDTA solution (Thermo
Scientific).Animal models
All animal experiments were conducted in compliance
with the national legislation on laboratory animals' pro-
tection and with the approval of the Ethics Committee
for Animal Research (Lund University, Sweden). Two
animal models were used in this study, NMRI-Nu with
subcutaneous (s.c.) xenografts and SCID mice with
intra-tibial xenografts. NMRI-Nu mice (6-to-8-week-old,
Taconic; Ry, Denmark) were inoculated in the right flank
by s.c. injection of 5 to 8 × 106 cells in a 200 μL of cell
suspension of 1:1 mixture of medium with Matrigel (BD
Biosciences; San Jose, CA, USA). Tumours were allowed
to develop for 6 to 8 weeks. SCID mice (6-to-8-week-old
male, Charles River; Charles River, NJ, USA) were main-
tained under isoflurane anaesthesia during surgery. For
intra-tibial inoculations, the tibia was punctured using a
23-gauge needle, and 1 × 105 LNCaP cells were injected
into the tibial cavity. The puncture was closed with bone
wax, the incision sutured and the animals received a pallia-
tive dose of Temgesic (Buprenorphine, RB Pharmaceuticals;
Richmond, VA, USA) once daily for 3 days post-surgery.
Intra-tibial tumours were allowed to develop for 8 to 10
weeks. Additionally, a group of normal NMRI mice (n = 4)
were used to study the distribution of the tracer in healthy
animals. Animals were euthanized by intraperitoneal (i.p.)
injection with 20 μL per gram of body weight Ketalar-
Rompun solution. (Ketalar, 10 mg/mL; Pfizer; New York,
NY, USA, and Rompun, 1 mg/mL; Bayer Animal Health;
Monheim, Germany).Biodistribution studies
Biodistribution studies were conducted to evaluate the up-
take of 111In-DTPA-11B6 in human prostate cancer
LNCaP xenografts. Mice (n = 3 to 5 per time point) re-
ceived 111In-DTPA-11B6 (0.4 to 0.6 MBq, 20 μg of mAb,
in approximately 100 μL of PBS) through intravenous (i.v.)
tail vein injection. Blood and organs (including tumour)
were taken at 4, 24, 48, 72 and 168 h post-injection,
weighed and measured in a NaI(TI) well counter (Wallac
Wizard 1480 Wizard, Perkin Elmer). The activity injected
into each animal was measured and used to determine the
count rate, in comparison with a standard solution of
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and physical decay.
Organ-specific uptake values were calculated as percent
injected activity per gram of tissue (%IA/g) or percent
injected activity (%IA). Among the organs resected were
the lateral and ventral prostate, from now on referred to
as prostate, and the submandibular glands, from now on
called salivary glands.
In vivo binding specificity
In vivo competitive binding studies were performed to
investigate the specificity of 111In-DTPA-11B6 to hK2. A
40-fold excess of non-labelled 11B6 was i.v. injected as a
co-injection or at 168, 120 and 48 h prior to an i.v. injec-
tion of 111In-DTPA-11B6 in hK2-positive LNCaP xeno-
grafts (n = 3 to 4 per pre-injection time point). Blood
and organs (including tumour) were taken at 48 h post-
injection of 111In-DTPA-11B6, weighed and analysed as
above. The binding specificity was also evaluated by
measuring the uptake of 111In-DTPA-11B6 in hK2-
negative DU145 xenografts expressing low levels of hK2
(n = 3) at 48 h post-injection, which are considered to be
hK2-negative when compared to other PCa tumours.
Small animal PET/SPECT/CT/MR imaging
Animals were anaesthetized with 2% to 3% isoflurane gas
(Baxter; Deerfield, IL, USA) for all imaging purposes. For
SPECT/CT imaging, NMRI-nu mice with s.c. LNCaP xeno-
grafts (48 h post-injection, n = 4; 72 h post-injection, n = 3;
pre-dosed 11B6, n = 4; co-injection 5A10, n = 3) and SCID
mice (n = 3) with intra-tibial LNCaP xenografts were i.v.
injected with approximately 8 MBq of 111In-DTPA-11B6
(approximately 20 μg of mAb in 150 μL of PBS) and im-
aged, for 1 h, by using a preclinical SPECT/CT scanner
(NanoSPECT/CT Plus, Bioscan; Washington, DC, USA)
with the NSP-106 multi-pinhole mouse collimator. SPECT
data were reconstructed using HiSPECT software (SciVis;
Goettingen, Germany). CT imaging was done before each
whole-body SPECT.
Pre-dosed mice were given 0.8 mg of non-labelled mAb
48 h prior to injection of radiolabelled mAb. Co-injections
with 111In-DTPA-11B6 and 1.5 mg of fPSA-specific 5A10
were done to evaluate the possible cross-reactivity of
111In-DTPA-11B6 with PSA.
The legs of the SCID mice were resected after imaging,
and the radioactivity in the intra-tibial xenografted and the
non-xenografted leg were measured in the NaI(Ti) well
counter. Radiolabelling for SPECT of intra-tibial xenografts
demonstrated 95% radiochemical purity and was injected
directly without NAP-5 column purification. Verification
of the intra-tibial tumour growth was performed by MR
imaging. The legs were imaged in an 11.7 T (500 MHz for
protons) vertical bore MR camera (Agilent Technologies;
Palo Alto, CA, USA) equipped with Varian 88/55 micro-imaging triple axis gradient coil (1 T/m maximum gradient
strength). Samples were placed in the centre of a Millipede
imaging probe (Agilent Technologies; Santa Clara, CA,
USA), with an inner diameter of 40 mm.
For PET/CT imaging, mice with LNCaP xenografts
were i.v. injected with approximately 12 MBq 18F-FDG
(n = 4) or approximately 12 MBq18F-Choline (n = 4) and
imaged 1 h post-injection using a Bioscan NanoPET/CT
Plus preclinical scanner for approximately 15 min. Both
SPECT/CT and PET/CT images were analysed using
InVivoScope 2.0 software (inviCRO; Boston, MA, USA),
and ROIs were drawn using the CT image as anatomical
reference.
Autoradiography and staining
After SPECT imaging at 48 and 72 h, s.c. tumours were
resected and embedded in Tissue-Tek® O.C.T™ com-
pound (Sakura Finetek; Alphen aan den Rijn, The
Netherlands) and frozen on dry ice. The frozen samples
were cryosectioned with a thickness of 20 μm for auto-
radiography analysis on a Cyclone Storage Phosphor
System. The tumour sections were stained with Mayer's
hematoxylin and chromotrope 2R, Ch2R (both from
Histolab; Gothenburg, Sweden), and scanned using a
light-microscope slide scanner (Mirax Midi, Carl Zeiss;
Oberkochen, Germany). Thresholds for the autoradio-
grams were set in ImageJ v.1.47.
Statistical analysis
Data was analysed using the unpaired, two-tailed Student's
t test (Microsoft Excel or GraphPad Prism v.4). Differences
at the 95% confidence level (P < 0.05) were considered to be
statistically significant. Figures were produced with Graph-
Pad Prism v.4 (GraphPad Software). All biodistribution data
are shown as an average %IA/g of 3 to 5 animals ± SD
(standard deviation) unless otherwise stated.
Results
Radiolabelling and stability
A radiolabelling yield of 58.6% ± 12.5% (n = 3) was
achieved. The radiochemical purity after NAP-5 purifica-
tion was >99% and for labelling with higher activities for
imaging a specific activity of 0.30 ± 0.03 MBq/μg (n = 3).
111In-DTPA-11B6 was stable in PBS buffer at 4°C and in
mouse serum at 37°C. More than 95% of the radioacti-
vity was still attached to the radioconjugate after 1 week
in both conditions.
Binding kinetics with surface plasmon resonance
The binding kinetics of 11B6 were analysed on a Biacore
instrument. The affinity of 11B6 was high for hK2 and, al-
though conjugation seemed to affect the association con-
stant (ka) and the dissociation constant (kd), the calculated
binding affinities (KD; calculated as kd/ka) were similar.
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to be (5.1 ± 2.2) × 10−11 M and 6.6 × 10−11 ± 0.46 × 10−11
M, respectively. Representative sensorgrams of the 11B6
and DTPA-11B6 binding kinetics are shown in the supple-
mentary data (Additional file 1: Figure S1A,B).Figure 1 Biokinetics of 111In-DTPA-11B6. (a) Biodistribution of 111In-DTP
to 5 animals per time point. (b) Biodistribution of 111In-DTPA-11B6 in norm
compared to tumour-bearing mice but with a retained high uptake in the
over the time of the experiment. Right, tumour-to-muscle ratio. This high, i
in SPECT/CT images. (See Figure 3)Biodistribution studies
The biodistribution of 111In-DTPA-11B6 in NMRI mice
with LNCaP xenografts revealed that the accumulation in
tumour tissue increased threefold from 4 h (5.9 ± 3.6%IA/g)
to a maximum at 48 h (19 ± 0.78%IA/g) (Figure 1a). BloodA-11B6 in NRMI nude mice carrying LNCaP xenografts. %IA/g ± SD, 3
al NMRI mice at 48 h. An overall lower %IA/g was observed as
salivary glands. (c) Left, tumour-to-blood ratio is steadily increasing
ncreasing ratio explains the good visualization and contrast observed
Table 2 Tumour-to-tissue (T/Ti) ratios of 111In-DTPA-11B6
in NMRI nude mice carrying LNCaP xenografts
4 h 24 h 48 h 72 h 168 h
Heart 0.99 ± 0.44 3.0 ± 0.13 6.2 ± 1.5 6.7 ± 1.7 38 ± 58
Lung 0.75 ± 0.43 2.3 ± 0.21 3.5 ± 1.4 3.7 ± 1.4 5.2 ± 1.5
Liver 0.79 ± 0.34 2.2 ± 0.44 3.8 ± 0.96 3.5 ± 1.0 4.4 ± 0.28
Spleen 0.99 ± 0.45 2.5 ± 0.46 3.2 ± 0.27 3.1 ± 0.57 3.7 ± 0.83
GI tract 3.5 ± 1.6 9.8 ± 1.6 17 ± 3.5 14 ± 1.3 30 ± 8.2
Kidneys 0.62 ± 0.25 2.0 ± 0.24 3.9 ± 1.2 4.2 ± 0.71 6.8 ± 1.5
Salivary 2.3 ± 0.98 1.9 ± 0.24 1.8 ± 0.35 1.2 ± 0.32 1.2 ± 0.37
Muscle 10 ± 5 11 ± 5.3 25 ± 21 16 ± 4.8 40 ± 11
Bone 3.5 ± 0.81 7.0 ± 1.4 7 ± 3.9 10 ± 3.6 9.2 ± 2.6
Brain 12 ± 6.6 39 ± 4.5 75 ± 31 74 ± 22 118 ± 13
Prostate 3.7 ± 1.3 3.5 ± 0.99 12 ± 7.0 8.2 ± 3.0 12 ± 1.5
Testes 1.9 ± 0.82 5.0 ± 0.77 11 ± 2.2 9.5 ± 2.4 11 ± 3.9
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over time, resulting in a tumour-to-blood ratio of 1.6
after 3 days and 2.4 at 1 week (Table 1). All organs
showed constant, low uptake and low tissue-to-blood
ratios (Ti/B), except for the salivary glands and highly
vascularized organs, such as the spleen, liver and lung,
suggesting no active antibody accumulation. Further-
more, the spleen, liver and lung showed steady increase
in tumour-to-tissue (T/Ti) ratios. The T/Ti ratios in-
creased more than threefold between 4 h and 1 week
(Table 2). The salivary gland accumulation followed a
different pattern, more similar to that of the tumour,
reaching a maximum at 1 week (13.6 ± 3.6%IA/g). This
elevated uptake could be due to cross-reactivity of
111In-DTPA-11B6 since most mice kallikreins are abun-
dant in this organ [27], although mice are naturally de-
ficient hK2 [16]. The high level of mice kallikreins in
the salivary glands could be an explanation to retained
salivary gland uptake even after pre-dosing (Figure 2b).
A similar, but slightly lower, salivary gland uptake (9.0
± 2.0%IA/g) was seen in tumour-free NMRI mice at 48
h (Figure 1b). These mice exhibited a lower overall
organ uptake of the tracer, which could be explained by
the lack of shedded antigen circulating in the blood.
At 1 week, the steadily increasing T/Ti ratios for
blood and muscle were 2.4 ± 0.62 and 40 ± 11, respect-
ively (Table 1, Table 2 and Figure 1c). Particularly high
increases in T/Ti were seen for the brain with a T/Ti
of 118 ± 13 at the end of the study. The high brain
T/Ti could probably be explained by the tight junc-
tions of the epithelial cells of the brain vasculature and
blood-brain barrier and then only reflecting the blood
content.Table 1 Tissue-to-blood (Ti/B) ratios of 111In-DTPA-11B6
in NMRI nude mice carrying LNCaP xenografts
4 h 24 h 48 h 72 h 168 h
Tumour 0.23 ± 0.10 0.80 ± 0.12 1.6 ± 0.41 1.7 ± 0.44 2.4 ± 0.62
Heart 0.23 ± 0.02 0.26 ± 0.03 0.26 ± 0.03 0.24 ± 0.02 0.22 ± 0.16
Lung 0.33 ± 0.12 0.36 ± 0.07 0.48 ± 0.12 0.43 ± 0.07 0.47 ± 0.05
Liver 0.28 ± 0.04 0.36 ± 0.02 0.43 ± 0.03 0.44 ± 0.04 0.55 ± 0.14
Spleen 0.23 ± 0.06 0.34 ± 0.09 0.50 ± 0.09 0.49 ± 0.07 0.64 ± 0.06
GI tract 0.07 ± 0.004 0.08 ± 0.003 0.09 ± 0.01 0.11 ± 0.04 0.08 ± 0.01
Kidneys 0.35 ± 0.05 0.40 ± 0.03 0.41 ± 0.05 0.37 ± 0.04 0.35 ± 0.03
Salivary 0.10 ± 0.01 0.44 ± 0.08 0.86 ± 0.11 1.3 ± 0.11 2.1 ± 0.38
Muscle 0.02 ± 0.003 0.08 ± 0.03 0.09 ± 0.05 0.09 ± 0.02 0.06 ± 0.01
Bone 0.07 ± 0.03 0.12 ± 0.01 0.34 ± 0.34 0.17 ± 0.05 0.27 ± 0.07
Brain 0.02 ± 0.003 0.02 ± 0.003 0.02 ± 0.003 0.02 ± 0.001 0.02 ± 0.003
Prostate 0.06 ± 0.01 0.24 ± 0.04 0.14 ± 0.04 0.19 ± 0.04 0.20 ± 0.05
Testes 0.12 ± 0.02 0.16 ± 0.02 0.15 ± 0.02 0.17 ± 0.02 0.27 ± 0.20In vivo binding specificity
Pre-injection with an excess of cold antibody (0.8 mg of
cold mAb) significantly decreased tumour accumulation
of the labelled conjugate. The tumour accumulation was
7.2 ± 0.53%IA/g at 48 h post-injection in mice that re-
ceived a blocking dose of 11B6 and was significantly
lower to the 17 ± 5.2%IA/g observed in non-blocked
mice (P = 0.03) (Figure 2a). Furthermore, the DU145 hK2-
negative xenografts showed significantly lower (P = 0.01)
tumour accumulation for 111In-DTPA-11B6, 4.8 ± 0.86%
IA/g compared to 17 ± 5.2%IA/g at 48 h (Figure 2a).
The difference in specific uptake between tumour
samples from pre-dosed mice (n = 16) and the reference
group (n = 4) deteriorated with decreasing tumour weight,
which skewed the tumour uptake data for the 120 h and
co-injection time points (Figure 2b). For all groups, the
specific uptake increased with tumour volume, but it was
less in the pre-dosed groups (Figure 2c). This demonstrates
that it is possible to block the uptake with cold 11B6
and remains effective over the span of 1 week. In other
organs, no or small deviations from the non-blocked
group were observed.
Small animal PET/SPECT/CT/MR imaging
Representative SPECT/CT images of LNCaP xenografts
measured 2 to 3 days post-injection of 111In-DTPA-11B6
are shown in Figure 3a. The activity distribution in the
SPECT images, with a high tumour-to-background con-
trast, is comparable to the high tumour-to-tissue ratios
at these time points (Table 1). The high contrast was
most likely attributed to the high affinity and specificity
of the tracer.
The ROI analysis showed that the ratio of tumour to soft
tissue of the contralateral leg was 6.1 ± 1.5 at 48 h (n = 4)
and 6.8 ± 1.7 at 72 h (n = 3). ROI analysis also showed a
tumour-to-heart ratio of 1.7 ± 0.7 and a tumour-to-liver
Figure 2 In vivo binding specificity of 111In-DTPA-11B6 in NRMI nude mice. (a) Dot plot of tumour accumulation in blocked LNCaP,
non-blocked LNCaP xenografts (hK2+) and DU145 (hK2−). There was a significant difference in active uptake between non-blocked LNCaP
xenografts and the other groups. (b) Distribution of 111In-DTPA-11B6 48 h post-injection in LNCaP xenografted NMRI mice, shown as %IA/g ± SEM
with pre-dosing of 0.8 mg of cold 11B6 antibody. (c) Dot plot with linear regression for pre-dosing and no pre-dosing as function of tumour
weight. This shows that %IA increases with tumour weight for both pre-dosed and normal uptake but that the uptake increases more in tumours
with no pre-dosing. The slope calculated from linear regression was 6.1 ± 0.27%IA/g for the pre-dosed groups and 14 ± 1.2%IA/g with no pre-dosing.
The R2 value was 0.97 for the pre-dosed groups and 0.99 for xenografts without pre-dosing. As %IA/g increases with smaller tumour volume this could
explain the large difference seen in (b) between the different pre-dosing groups. By analysing %IA instead, it seems that the effect of pre-dosing is
retained over the studied time interval and that 11B6 in fact has a long tumour retention.
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Figure 3 Preclinical SPECT/CT and MR images. (a) SPECT/CT images of four NMRI nude mice with LNCaP xenografts on the right flank. Top
left, 48 h post-injection; Top right, 72 h post-injection; Bottom left, blocked mouse pre-injected with 0.8 mg of cold antibody 48 h prior to injection of
radiolabelled antibody. Bottom right, image of a mouse at 48 h co-injected with 1.5 mg of unlabelled 5A10, which did not block the tumour uptake of
111In-DTPA-11B6. It should be noted that for the calculation of the T/B ratio (1.6) in the biodistribution and for the ROI analysis of the SPECT images
with a derived T/heart ratio of 1.7, the whole tumour is taken into account. Since the colour scale in the SPECT image is scaled partially based upon
high uptake areas of the tumour, a direct comparison between these (which are strikingly visible) and the T/B or T/heart (ROI) is not totally fair. (b)
SPECT/MR images of SCID mice with intra-tibial xenograft in the left hind limb. Left, SPECT/CT side view, 48 h post-injection; middle, transverse SPECT/
CT image slices of the same mouse. The accumulation of 111In-DTPA-11B6 in intra-tibial tumours is clearly shown in both images. Right, MR image of
the same animal, where the growth of the intra-tibial tumour is well visualized (arrow).
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spectively, at 72 h. This is similar to the tumour-to-tissue
ratios derived from the biodistribution data. Interestingly,
an obvious heterogeneous distribution of activity could beseen in the SPECT images of the tumours, later confirmed
in autoradiograms (Figure 4a). High accumulation of activ-
ity was also detected in the salivary glands. For the blocked
mice (n = 4), the ROI ratio at 48 h of the tumour to the
Figure 4 Autoradiograms and images of H- and Ch2R-stained tumour sections. (a) A heterogeneous distribution of activity with higher
intensities in areas corresponding to a more intense level of staining with H and Ch2R, 48 h (left) and 72 h (right). (b) Stained sections and
autoradiograms of two tumours resected at 48 h from mice pre-dosed with 0.8 mg of cold 11B6 48 h prior to injection with 111In-DTPA-11B6.
(c) An autoradiogram and stained section of a submandibular gland at 48 h. This normal organ shows less heterogeneity in activity distribution
and hematoxylin and Ch2R staining.
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0.41 and 0.87 ± 0.07, respectively. The salivary gland up-
take was not associated with detached indium-labelled
CHX-A″-DTPA, as confirmed with SPECT/CT (Figure 5).
We also checked whether 111In-DTPA-11B6 could be
used to detect PCa skeletal lesions. Osseous tumours
were established in SCID mice through intra-tibial in-
jections of LNCaP cells in the left hind limb, and
SPECT/CT images were performed after i.v. injection
of 111In-DTPA-11B6. The legs were resected and mea-
sured in the NaI(Ti) well counter, using the right non-
xenografted legs as a negative control. The data showed
an at least twofold uptake of 111In-DTPA-11B6 in the
tibia compared to the reference leg, some of which
might be due to inflammation induced by the surgical
procedure. MR imaging confirmed tumour develop-
ment within the bone (Figure 3b).
Although 111In-labelled 11B6 showed a good stability
in murine serum, we investigated whether the high up-
take seen in the salivary glands could be a result of
indium-labelled CHX-A″-DTPA, this was not confirmed
(Figure 5, left). PET/CT images of NMRI-nude mice
with s.c. LNCaP showed that 18F-FDG and 18F-Choline
were hardly able to visualize the LNCaP xenografts, as
compared to 111In-DTPA-11B6 (Figure 5, right). ROI
analysis showed that the ratio of these xenografts to the
soft tissue of the contralateral leg was 1.1 ± 0.38 for 18F-
FDG (n = 4) and 1.09 ± 0.45 for 18F-Choline (n = 4).Autoradiography and staining
Activity accumulation was confirmed to be heterogeneous
in tumour sections at both 48 and 72 h. Comparative au-
toradiograms between the pre-dosed (Figure 4b) and non-
pre-dosed mice (Figure 4a) showed that for the former, ac-
tivity was confined to areas with high hematoxylin and
Ch2R staining, i.e. areas of high cell density, whereas the
activity in tumours from pre-dosed animals was found in
areas with low hematoxylin and Ch2R staining. This dif-
ference could be due to an active uptake in the viable re-
gions, blocked in the latter by pre-dosing with cold
antibody. The activity distribution was more homogenous
in the salivary glands of non-pre-dosed mice, indicating
an uptake in all glandular structures in this organ
(Figure 4c).
Discussion
There is a clinical need for improved methods to detect
and stage prostate cancer. The imaging of androgen-
regulated prostate-specific antigens overexpressed in
prostate cancer, such as PSA, would be advantageous for
diagnosing and monitoring the disease. In this study, we
demonstrated the ability for a novel radiotracer targeting
free hK2, a prostate-specific kallikrein homologous to
PSA, to specifically target and image hK2 expression in
AR- and hK2-positive LNCaP xenografts. Significantly,
111In-DTPA-11B6 exhibited strong targeting in both
subcutaneous and intra-tibial bone xenografts, with a
Figure 5 111In-CHX-A″-DTPA SPECT/CT and 18 F-FDG and 18 F-Choline PET/CT images. SPECT/CT images (left) of non-tumour bearing NMRI
nude mice showing localization of 111In-CHX-A″-DTPA in the kidneys (0.5 h post-injection). PET/CT images of s.c. LNCaP xenografts 1 h after injection
with 18 F-FDG and 18 F-Choline, respectively (middle and right). Tumours, indicated by red circles, were not well visualized with these radiotracers.
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ous tumours (Figure 1a). The elevated uptake of 111In-
DTPA-11B6 in the salivary glands was an unexpected re-
sult of this study; however, several glandular kallikreins
are synthesized by the salivary glands in mice [27]. Since
we see an uptake in the salivary glands of both NMRI
nude and normal non-xenografted NMRI mice, it seems
likely that 111In-DTPA-11B6 cross-reacts with kallikreins
expressed in the salivary glands of these mice.
The tumour accumulation of 111In-DTPA-11B6 was
hK2-specific, as verified by the low accumulation in the
negative control, DU145 xenografts and by competitive
binding assays using excess cold non-labelled antibody.
Furthermore, tumour accumulation slowly decreased
after day 2 but was not as rapid as blood clearance at
the same time points. This gave a steadily increasing pat-
tern in tumour-to-blood (T/B) ratios over time, from
1.6 ± 0.41 at 48 h to 2.4 ± 0.62 at 1 week (Table 1).
Though the blood clearance of 111In-11B6 is comparable
to other full-sized IgGs, the high tumour uptake, an in-
creasing T/B ratio and a comparatively low liver uptake,
implicates the usefulness of this radiotracer for imaging.
Further, most tissues seem to display blood kinetics, ex-
cept for a faint active uptake by the liver, spleen and
lung compared to the high accumulation rate observed
in the tumour and salivary gland tissue. Tissues such asthe muscle and brain gave high T/Ti ratios of 40 ± 11
and 118 ± 13, respectively, at 1 week, whereas the liver
and spleen have lower T/Ti ratios of 4.4 ± 0.28 and 3.7 ±
0.83, respectively. There could be some concerns raised
about 111In-DTPA-11B6 binding to free hK2 in the
blood. However, the blocking with cold non-labelled
antibody does not seem to change the amount of the
blood activity significantly at 48 h post-injection. Also,
in the control group with DU145 xenografts, there was
no significant difference in blood activity at 48 h, but a
significant difference in tumour uptake was found. One
interesting observation from the pre-dosing studies was
that the %IA as a function of the tumour size (Figure 2c)
differed between the pre-dosed (all pre-dosed/co-injected
groups) and non-blocked tumours if these were not too
small in tumour size. This explains the large deviation for
the pre-dosing at 120 h in Figure 2b. These results also
suggest a long tumour retention of the antibody, some-
thing also seen in the T/B ratio.
Despite the high sequence homology between PSA
and hK2, the 11B6 antibody did not show any cross-
reactivity to PSA. This was supported by the fact that
co-injection with a high dose of PSA-specific 5A10 anti-
body did not hinder the uptake of 111In-DTPA-11B6 in
LNCaP xenografts (Figure 3a). This highlights the possi-
bility of concurrent use. As both KLK3 and KLK2 genes
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theorize that the 11B6 antibody could be used to image
AR signalling in prostate cancer in a similar fashion to
that reported with 5A10 [18].
In addition, the tracer's specificity was further confirmed
by the distinct differences seen between pre-dosed and
non-pre-dosed LNCaP xenografts. This difference was
also validated by both SPECT and in excised xenografts
(Figure 3a, Figure 2). Furthermore, autoradiograms
demonstrate that the localization of the labelled anti-
body to a dense PCa tissue could be changed or blocked
by pre-dosing (Figure 4a,b). Although the underlying
physiology remains unknown, this could be due to a de-
crease in an active uptake and/or the blocking of a pool
of free hK2 in tumour tissue.
Based on our data, we believe that radiolabelled mono-
clonal antibodies such as 111In-DTPA-11B6 have an im-
mense value for use in the imaging, staging and evaluation
of advanced PCa. The favourable T/Ti ratios also suggest
that 11B6 could be used as a moiety for delivering high
absorbed doses in radioimmunotherapy, whereas 111In-
radiolabelled 11B6 could potentially be used for patient-
individualized dose planning.
Conclusions
111In-DTPA-11B6 is a new radiotracer for SPECT/CT im-
aging of hK2-expressing prostate cancer. To our know-
ledge, this is the first study using hK2 as a target for
immune imaging. The favourable biokinetics, high tumour
accumulation and low normal organ uptake observed with
111In-DTPA-11B6 underscore its potential as a novel PCa
imaging agent for the detection of metastatic PCa and for
monitoring anti-androgen therapy. Because of its im-
munogenicity, the murine form of 11B6 is not suitable for
future clinical trials. Nevertheless, the therapeutic poten-
tial of 11B6 in radioimmunotherapy applications is under
investigation, as well as a humanised version of 11B6,
which is currently in development.
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